{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T07:20:55Z","timestamp":1773213655613,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,3,20]],"date-time":"2019-03-20T00:00:00Z","timestamp":1553040000000},"content-version":"am","delay-in-days":353,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"Department of Defense","doi-asserted-by":"publisher","award":["DoD-W81XWH1110795"],"award-info":[{"award-number":["DoD-W81XWH1110795"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute of Health and National Institute for Drug Addiction","doi-asserted-by":"publisher","award":["DA039143"],"award-info":[{"award-number":["DA039143"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.bbrc.2018.03.028","type":"journal-article","created":{"date-parts":[[2018,3,10]],"date-time":"2018-03-10T20:34:08Z","timestamp":1520714048000},"page":"597-602","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Altered metabolism of synthetic cannabinoid JWH-018 by human cytochrome P450 2C9 and variants"],"prefix":"10.1016","volume":"498","author":[{"given":"Amy L.","family":"Patton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn A.","family":"Seely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azure L.","family":"Yarbrough","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Fantegrossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura P.","family":"James","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith R.","family":"McCain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoichi","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul L.","family":"Prather","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffery H.","family":"Moran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Radominska-Pandya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2018.03.028_bib1","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3109\/15563650.2011.609822","article-title":"Severe toxicity following synthetic cannabinoid ingestion","volume":"49","author":"Lapoint","year":"2011","journal-title":"Clin. Toxicol."},{"key":"10.1016\/j.bbrc.2018.03.028_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021917","article-title":"Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in\u00a0vitro and in\u00a0vivo cannabinoid 1 receptor affinity and activity","volume":"6","author":"Brents","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrc.2018.03.028_bib3","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1093\/jat\/bkv142","article-title":"Death associated with the use of the synthetic cannabinoid ADB-FUBINACA","volume":"40","author":"Shanks","year":"2016","journal-title":"J.\u00a0Anal. Toxicol."},{"key":"10.1016\/j.bbrc.2018.03.028_bib4","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1056\/NEJMp1505328","article-title":"Synthetic cannabinoid-related illnesses and deaths","volume":"373","author":"Trecki","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.bbrc.2018.03.028_bib5","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3109\/03602532.2013.849268","article-title":"Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review","volume":"46","author":"Stout","year":"2014","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.bbrc.2018.03.028_bib6","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.lfs.2013.09.017","article-title":"Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Delta(9)-THC: mechanism underlying greater toxicity?","volume":"97","author":"Fantegrossi","year":"2014","journal-title":"Life Sci."},{"key":"10.1016\/j.bbrc.2018.03.028_bib7","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1124\/dmd.111.040709","article-title":"Conjugation of synthetic cannabinoids JWH-018 and JWH-073, metabolites by human UDP-glucuronosyltransferases","volume":"39","author":"Chimalakonda","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bbrc.2018.03.028_bib8","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1124\/dmd.112.047530","article-title":"Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2\/Spice: identification of novel cannabinoid receptor ligands","volume":"40","author":"Chimalakonda","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bbrc.2018.03.028_bib9","doi-asserted-by":"crossref","first-page":"6381","DOI":"10.1021\/ac201377m","article-title":"Solid-phase extraction and quantitative measurement of omega and omega-1 metabolites of JWH-018 and JWH-073 in human urine","volume":"83","author":"Chimalakonda","year":"2011","journal-title":"Anal. Chem."},{"key":"10.1016\/j.bbrc.2018.03.028_bib10","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1111\/1556-4029.12216","article-title":"K2 toxicity: fatal case of psychiatric complications following AM2201 exposure","volume":"58","author":"Patton","year":"2013","journal-title":"J.\u00a0Forensic Sci."},{"key":"10.1016\/j.bbrc.2018.03.028_bib11","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.abb.2006.10.028","article-title":"CYP2E1 active site residues in substrate recognition sequence 5 identified by photoaffinity labeling and homology modeling","volume":"459","author":"Collom","year":"2007","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.bbrc.2018.03.028_bib12","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/FPC.0b013e3283349e84","article-title":"Cytochrome P450 2C9-CYP2C9","volume":"20","author":"Van Booven","year":"2010","journal-title":"Pharmacogenetics Genom."},{"key":"10.1016\/j.bbrc.2018.03.028_bib13","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jphs.2017.08.006","article-title":"Function of 38 variants CYP2C9 polymorphism on ketamine metabolism in\u00a0vitro","volume":"135","author":"Zheng","year":"2017","journal-title":"J.\u00a0Pharmacol. Sci."},{"key":"10.1016\/j.bbrc.2018.03.028_bib14","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/FTD.0000000000000437","article-title":"Combined effect of CYP2B6 genotype and other candidate genes on a steady-state serum concentration of methadone in opioid maintenance treatment","volume":"39","author":"Kringen","year":"2017","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.bbrc.2018.03.028_bib15","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/j.1365-2710.2007.00870.x","article-title":"Pharmacogenetics of acenocoumarol: CYP2C9, CYP2C19, CYP1A2, CYP3A4, CYP3A5 and ABCB1 gene polymorphisms and dose requirements","volume":"32","author":"Saraeva","year":"2007","journal-title":"J.\u00a0Clin. Pharm. Therapeut."},{"key":"10.1016\/j.bbrc.2018.03.028_bib16","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0140-6736(98)04474-2","article-title":"Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications","volume":"353","author":"Aithal","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.bbrc.2018.03.028_bib17","doi-asserted-by":"crossref","first-page":"9390","DOI":"10.1021\/ac4024704","article-title":"Targeted metabolomic approach for assessing human synthetic cannabinoid exposure and pharmacology","volume":"85","author":"Patton","year":"2013","journal-title":"Anal. Chem."},{"key":"10.1016\/j.bbrc.2018.03.028_bib18","doi-asserted-by":"crossref","first-page":"4228","DOI":"10.1021\/ac2005636","article-title":"Quantitative measurement of JWH-018 and JWH-073 metabolites excreted in human urine","volume":"83","author":"Moran","year":"2011","journal-title":"Anal. Chem."},{"key":"10.1016\/j.bbrc.2018.03.028_bib19","first-page":"835","article-title":"The Hill equation revisited: uses and misuses","volume":"11","author":"Weiss","year":"1997","journal-title":"Faseb. J. Official publ. Fed. Am. Soc. Exp. Biol."},{"key":"10.1016\/j.bbrc.2018.03.028_bib20","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2174\/157488407779422302","article-title":"The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance","volume":"2","author":"Rosemary","year":"2007","journal-title":"Curr. Clin. Pharmacol."},{"key":"10.1016\/j.bbrc.2018.03.028_bib21","first-page":"391","article-title":"The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects","volume":"76","author":"Lynch","year":"2007","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.bbrc.2018.03.028_bib22","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1046\/j.1365-2125.1998.00721.x","article-title":"Cytochrome P4502C9: an enzyme of major importance in human drug metabolism","volume":"45","author":"Miners","year":"1998","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bbrc.2018.03.028_bib23","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1093\/carcin\/22.8.1323","article-title":"Association of CYP2C9 genotypes leading to high enzyme activity and colorectal cancer risk","volume":"22","author":"Martinez","year":"2001","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.bbrc.2018.03.028_bib24","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1742-7843.2006.pto_304.x","article-title":"Inhibitory effect of 5-fluorouracil on cytochrome P450 2C9 activity in cancer patients","volume":"98","author":"Gunes","year":"2006","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.bbrc.2018.03.028_bib25","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.steroids.2006.11.016","article-title":"Phenylalanine(90) and phenylalanine(93) are crucial amino acids within the estrogen binding site of the human UDP-glucuronosyltransferase 1A10","volume":"72","author":"Starlard-Davenport","year":"2007","journal-title":"Steroids"},{"key":"10.1016\/j.bbrc.2018.03.028_bib26","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1021\/bi0519001","article-title":"Phenylalanine 90 and 93 are localized within the phenol binding site of human UDP-glucuronosyltransferase 1A10 as determined by photoaffinity labeling, mass spectrometry, and site-directed mutagenesis","volume":"45","author":"Xiong","year":"2006","journal-title":"Biochemistry"},{"key":"10.1016\/j.bbrc.2018.03.028_bib27","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.biochi.2011.02.008","article-title":"Reduced catalytic activity of human CYP2C9 natural alleles for gliclazide: molecular dynamics simulation and docking studies","volume":"93","author":"Banu","year":"2011","journal-title":"Biochimie"},{"key":"10.1016\/j.bbrc.2018.03.028_bib28","first-page":"305","article-title":"Cannabinoid type 1 receptor gene polymorphism and macronutrient intake","volume":"5","author":"Caruso","year":"2012","journal-title":"J.\u00a0Nutrigenetics Nutrigenomics"}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X18305023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X18305023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T11:23:50Z","timestamp":1757762630000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X18305023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0006291X18305023"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2018.03.028","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Altered metabolism of synthetic cannabinoid JWH-018 by human cytochrome P450 2C9 and variants","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2018.03.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}